Charles River Laboratories Intl. Inc vs Wayfair Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Wayfair Inc trades at $105.74 (market cap $14.40B). The key difference: Charles River Laboratories Intl. Inc and Wayfair Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Wayfair Inc for 8 Days on average.
| CRL | W | |
|---|---|---|
Market Cap | $14.23B | $14.40B |
Volume | 1,176,885 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $119.05 |
52-Week Low | $149.93 | $57.40 |
Typical Hold Time | 33 Days | 8 Days |
Enterprise Value | $17.06B | $16.73B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Wayfair (W) trades at $105.13, up 0.63% with bullish technical signals and strong analyst support. The stock shows positive momentum with recent earnings beats and a consensus price target of $114.13. While revenue growth remains steady at $12.9B for 2026, the company continues to operate at a net loss margin of -2.49%, though operating cash flow improved to $665M. Recent developments include store expansion and new brand campaigns positioning for future growth.
Wayfair presents a growth opportunity with bullish technicals and analyst consensus, but faces fundamental challenges with persistent losses and high debt-to-asset ratio of 95.11%. The stock's upside potential depends on margin improvement and successful execution of retail expansion, while downside risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →